颅内CNS肿瘤放疗后MRI异常的国际共识定义
针对颅内中枢神经系统肿瘤放疗后MRI异常术语与定义异质性大的问题,由ESTRO、ESNR和EORTC联合多学科专家采用三轮德尔菲法达成共识。共识确定采用「Treatment-Related Imaging Abnormality,TRIA」作为统一术语,建立了possible TRIA和confirmed TRIA的定义。该框架旨在统一报告、支持临床决策并提高未来研究的可比性。
要点
- 推荐统一使用术语TRIA描述放疗后MRI异常,替代既往多种混杂表述
- 区分possible TRIA与confirmed TRIA,需结合MRI影像特征与随访变化判断
- MRI申请单应包含共识确定的最少必要信息,以便规范评估TRIA
核心结论
- 国际多学科德尔菲共识确定了TRIA作为颅内CNS肿瘤放疗后MRI异常的统一术语与定义框架,并由ESTRO、ESNR和EORTC联合认可
- 共识建立了possible TRIA与confirmed TRIA的明确定义,影像特征基础上的亚分类均获得高度一致同意
研究设计与样本
- 国际多学科德尔菲共识研究,由RING工作组内放射肿瘤、神经放射、神经肿瘤、肿瘤内科和神经外科专家参与
- 问卷由指导委员会制定并发放,采用三轮德尔菲法,共识阈值设定为≥75%同意率
- 最终共识由ESTRO、ESNR和EORTC正式认可,属于国际学会联合制定的共识定义框架
关键影像表现/征象
- TRIA指颅内CNS肿瘤放疗后在随访MRI上出现的治疗相关影像学异常,需结合影像特征与临床背景进行评估
- 影像特征基础上的TRIA亚分类标准在专家中显示高度一致性,但具体亚分类影像细节未在摘要中展开
诊断标准与关键数值
- possible TRIA与confirmed TRIA的定义通过德尔菲确定,共识阈值设定为≥75%专家同意,具体分级判定条款未在摘要中详述
- 为MRI申请单确定了用于规范TRIA评估的最少必要内容要素条目,但摘要未列出各条目的具体内容
- 摘要未报告敏感度、特异度、AUC、阈值或分级评分等定量诊断指标
临床应用与阅片要点
- 颅内CNS肿瘤放疗后随访MRI出现难以鉴别的新发病变时,应按共识框架考虑是否归类为TRIA
- 报告与临床沟通中采用TRIA统一术语,避免使用含义不一的其他描述词,以提高多学科沟通一致性
- 开具MRI申请单时应包含共识要求的最少必要信息,便于放射科按TRIA框架规范化评估
- 应用该框架有助于区分治疗反应、临床相关并发症与肿瘤生长,支持临床后续决策
局限性
- 摘要未报告德尔菲专家总人数、各轮应答率或退出情况,无法评价共识结果对目标人群的代表性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Magnetic resonance imaging (MRI) is essential for post-treatment surveillance of patients with intracranial central nervous system (CNS) tumours. However, interpretation is often complicated due to post radiotherapy MRI abnormalities. Current literature demonstrates substantial heterogeneity in terminology and definitions used to describe these MRI abnormalities, limiting clinical decision-making and comparability across studies. To address this, an international multidisciplinary Delphi consensus was conducted within the Radiation Imaging and Neuro-Oncology Group (RING). Questionnaires were developed by the steering committee and distributed to experts in radiation oncology, neuroradiology, neuro-oncology, medical oncology, and neurosurgery. A three-round Delphi method was employed, with consensus defined as ≥ 75% agreement. Consensus was reached on the applicability and definitions with adoption of the term Treatment-Related Imaging Abnormality (TRIA). Clear definitions for potential and confirmed TRIA were established. Subcategorization based on imaging features all demonstrated high agreement. For consistent application of the framework minimal essential elements for MRI request forms were identified. The final consensus was endorsed by ESTRO, ESNR and EORTC. This Delphi consensus provides a standardized framework for MRI abnormalities following radiotherapy for intracranial CNS tumours. The framework aims to harmonize reporting, support clinical decision-making, and improve comparability in future neuro-oncology research. Central nervous system neoplasms - Radiotherapy - Magnetic resonance imaging - Delphi Technique - Treatment-Related Imaging Abnormality (TRIA).
After radiotherapy for brain tumours changes can appear on follow-up MRI scans. These changes may represent treatment reactions, clinically relevant complications or tumour-related growth and distinguishing between them can be challenging. Many terms and definitions are currently used to describe these reactions, which complicates communication, clinical decision-making and research. This project brought together international experts in brain tumour treatment to agree on a standardised set of definitions. Using structured online surveys, the panel reached consensus on a concept called Treatment-Related Imaging Abnormality (TRIA). This standardised approach should improve clinical practice, support clearer communication, and enhance research in this field.
引用
- Lauwens, Zegers, Postma, et al. ESTRO, ESNR and EORTC consensus-based definition for MRI abnormalities after radiotherapy for intracranial central nervous system tumours. Neuro Oncol. 2026. PMID: 42623110. doi:10.1093/neuonc/noag194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。